<DOC>
	<DOCNO>NCT01231035</DOCNO>
	<brief_summary>The main objective project ass long-term prognostic impact residual platelet reactivity optimal antiplatelet therapy large cohort patient acute coronary syndrome undergo invasive strategy . Follow-up length least 24 month . The primary end-point study composite death , myocardial infarction , urgent target vessel revascularization , stent thrombosis stroke .</brief_summary>
	<brief_title>REsponsiveness CLOpidogrel Stent-related Events Acute Coronary Syndromes ( RECLOSE 2 - ACS )</brief_title>
	<detailed_description>This study mainly base registry 2000 consecutive patient acute coronary syndrome receive invasive treatment platelet reactivity clopidogrel treatment prospectively assess . In acute phase , blood sample platelet reactivity assessment obtain 12 18 hour 600 mg clopidogrel load . Platelet-rich plasma , obtain centrifuge whole blood 10 min 200 g , stimulate 10 M adenosine 5'-diphosphate ( ADP ) residual aggregation assess use APACT 4 light transmittance aggregometer . Platelet aggregation ( accord Born 's method ) evaluate consider maximal percentage platelet aggregation response stimulus . Patients platelet aggregation 10 µmol ADP ≥ 90th percentile control ( 70 % ) define non-responders . The assessment platelet reactivity repeat 6 month . The importance concomitant aspirin resistance also evaluate patient .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>acute coronary syndrome invasive treatment inhospital death due stent thrombosis , anticipate poor compliance dual antipletelet treatment least 6 month , premature discontinuation clopidogrel therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>acute cardiac syndrome</keyword>
	<keyword>stent thrombosis</keyword>
	<keyword>platelet function</keyword>
	<keyword>antiplatelet therapy</keyword>
</DOC>